olmesartan has been researched along with nifedipine in 8 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (nifedipine) | Trials (nifedipine) | Recent Studies (post-2010) (nifedipine) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 16,024 | 2,496 | 1,505 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Furuno, M; Higaki, J; Horiuchi, M; Inaba, S; Iwai, M; Kanno, H; Mogi, M; Okayama, H; Senba, I; Tomono, Y | 1 |
| Harada, N; Okajima, K; Shimozawa, N | 1 |
| Hayashi, T; Kitada, K; Kitaura, Y; Matsumoto, C; Matsumura, Y; Miyamura, M; Mori, T; Okada, Y; Sohmiya, K; Ukimura, A; Yamashita, C; Yoshioka, T | 1 |
| Dimitriadis, F; Kinoshita, Y; Martin, DT; Ohmasa, F; Oikawa, R; Oiwa, H; Saito, M; Satoh, I; Shimizu, S; Tomita, S; Tsounapi, P | 1 |
8 other study(ies) available for olmesartan and nifedipine
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Chemokine CCL2; Dihydropyridines; Drug Synergism; Femoral Artery; Imidazoles; Ligation; Male; Mice; Mice, Inbred C57BL; NADPH Oxidases; Neuropeptides; Nifedipine; rac GTP-Binding Proteins; rac1 GTP-Binding Protein; Superoxides; Tetrazoles; Tumor Necrosis Factor-alpha; Tunica Intima | 2009 |
AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Calcitonin Gene-Related Peptide; Capsaicin; Cells, Cultured; Ganglia, Spinal; Hypertension; Imidazoles; Insulin-Like Growth Factor I; Kidney; Losartan; Male; Myocardium; Nifedipine; Peptidyl-Dipeptidase A; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; RNA, Messenger; Sensory Receptor Cells; Telmisartan; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2009 |
Efficacy of olmesartan and nifedipine on recurrent hypoxia-induced left ventricular remodeling in diabetic mice.
Topics: Animals; Diabetes Mellitus, Type 2; Dietary Fats; Drug Therapy, Combination; Hypoxia; Imidazoles; Male; Mice; Mice, Obese; Myocytes, Cardiac; Nifedipine; Secondary Prevention; Tetrazoles; Ventricular Remodeling | 2010 |
Olmesartan ameliorates urinary dysfunction in the spontaneously hypertensive rat via recovering bladder blood flow and decreasing oxidative stress.
Topics: Aldehydes; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Disease Models, Animal; Hypertension; Imidazoles; Male; Malondialdehyde; Nerve Growth Factor; NF-E2-Related Factor 2; Nifedipine; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Wistar; Regional Blood Flow; Tetrazoles; Urinary Bladder; Urinary Bladder Diseases; Urodynamics | 2014 |